title: Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
abstract: The term oligomeropathies defines the neurodegenerative disorders associated with protein misfolding, where small soluble aggregates (oligomers 4-200 KDa) are the cause of neuronal dysfunction and are responsible for spreading the pathology. The ability of these soluble β-sheet conformers to induce neuronal damage has been investigated in direct challenge with the monomeric and fibrillary structures, showing that only the oligomeric species affected the neurons. β amyloid oligomers were initially purified from Alzheimer brains and obtained using synthetic peptides. Together with the neuronal death, synaptic dysfunction, loss of spines, and LTP impairment were seen with the direct application of β amyloid oligomers. Similar results have been described with proteins associated with other neurodegenerative disorders. The biological activities of oligomeric forms of α synuclein have been described in Parkinson's disease and Lewy body dementia. Detrimental effects have been associated with the oligomeric forms of prion, tau, and huntingtin, the key proteins in prion diseases, frontotemporal dementia, and Huntington's disease, respectively. The molecular mechanisms of the oligomer-related toxic effects can be summarized under three headings: nonspecific perturbance of cellular and intracellular membranes, specific interaction with various cellular entities, and amyloid pore channel formation. To characterize and distinguish oligomer actions better, we compared the ability of β amyloid and α synuclein oligomers to induce cognitive impairment when applied directly into the brain in the same acute mouse model. We also investigated the role of inflammatory components. © 2016 International Parkinson and Movement Disorder Society.
authors.affiliation: Departement of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche "Mario Negri,", Milano, Italy.
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Forloni
authors.affiliation: ASL 9, Ca' Foncello Hospital, Treviso, Italy.
authors.forename: Vladimiro
authors.initials: V
authors.lastname: Artuso
authors.affiliation: Departement of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche "Mario Negri,", Milano, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: La Vitola
authors.affiliation: Departement of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche "Mario Negri,", Milano, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Balducci
mesh_terms: D000544:Alzheimer Disease / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D006801:Humans; D010300:Parkinson Disease / Q000378:metabolism*; D057165:Proteostasis Deficiencies / Q000378:metabolism*; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D051844:alpha-Synuclein
keywords: aggregation; alpha synuclein; beta amyloid; neurodegeneration; spreading